The results indicated that early treatment with anti-PVRIG mAb significantly inhibited tumor growth (P < 0.0001; Fig. 4b) and extended the overall survival (P < 0.0001; Fig. 4c) of tumor-bearing mice compared with the control groups. This evidence concerns the gene PVRIG and neoplasm.